Class A, B and C CpG oligodeoxynucleotides targeting TLR9.
CpG ODNs are short synthetic single-stranded DNA molecules containing unmethylated oligodeoxynucleotides (ODNs). In detail, they comprise of CpG motifs, a cytosine triphosphate deoxynucleotide ("C") followed by a guanine triphosphate deoxynucleotide ("G"). CpG ODNs have been extensively studied as adjuvants. Pre-clinical studies, conducted in rodents and non-human primates, and human clinical trials have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses.
CpG ODNs are recognized by the Toll-like receptor 9 (TLR9), which is expressed on human B cells and plasmacytoid dendritic cells (pDCs), thereby inducing Th1-dominated immune responses.
Key features
- Offered in unmodified and labeled formats
- Every batch is functionally validated for performance
- Guaranteed free of contaminants to prevent TLR9-independent immune activation
- Also available as VacciGrade™ for safe and reliable in vivo applications
Applications
- Vaccine adjuvants to enhance immune responses, particularly Th1-type responses
- Cancer immunotherapy to boost anti-tumor immunity, especially in combination therapies
- Allergy and Autoimmunity Modulation to shift immune responses from Th2 to Th1
- Innate Immune Activation in Research to study TLR9-dependent pathways
- Therapeutic Development Tools to screen for TLR9 immunomodulatory drugs
CpG ODNs possess a partially or completely phosphorothioated (PS) backbone, as opposed to the natural phosphodiester (PO) backbone found in genomic bacterial DNA. Three major classes of stimulatory CpG oligodeoxynucleotides (ODNs) have been identified based on structural characteristics and activity on human peripheral blood mononuclear cells (PBMCs), in particular B cells and plasmacytoid dendritic cells (pDCs).
These three classes are Class A (Type D), Class B (Type K) and Class C.
